System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Randomized Controlled Trial Epublish

PubMed: 39683542 DOI: 10.3390/nu16234148

Influence of CReatine Supplementation on mUScle Mass and Strength After Stroke (ICaRUS Stroke Trial): A Randomized Controlled Trial.

Nutrients 16(23)

Authors: Juli T Souza, Marcos F Minicucci, Natália C Ferreira, Bertha F Polegato, Marina P Okoshi, Gabriel P Modolo, Filipe W Leal-Pereira, Bethan E Phillips, Philip J Atherton, Kenneth Smith, Daniel J Wilkinson, Adam L Gordon, Suzana E Tanni, Vladimir E Costa, Maria F Fernandes, Silméia G Bazan, Leonardo M Zornoff, Sérgio R Paiva, Rodrigo Bazan, Paula S Azevedo

Affiliations

  • Department of Internal Medicine, Medical School, São Paulo State University (UNESP), Botucatu 18618-970, SP, Brazil.
  • Department of Neuroscience and Mental Health, Medical School, São Paulo State University (UNESP), Botucatu 18618-970, SP, Brazil.
  • MRC-Versus Arthritis Centre for Musculoskeletal Ageing Research (CMAR) & NIHR Nottingham Biomedical Research Centre, University of Nottingham Medical School, Derby Uttoxeter Road, Derby DE22 3DT, UK.
  • Wolfson Institute of Public Health, Queen Mary University of London, London E1 4NS, UK.
  • Academic Centre for Healthy Ageing, Whipps Cross Hospital, Barts Health NHS Trust, London E1 1BB, UK.
  • Stable Isotopes Center, São Paulo State University (UNESP), Institute of Biosciences, Botucatu 18618-970, SP, Brazil.

Abstract

BACKGROUND/OBJECTIVES

The acute phase of stroke is marked by inflammation and mobility changes that can compromise nutritional status. This study was a randomized, double-blind, placebo-controlled trial evaluating the effectiveness of creatine supplementation for older people during seven days of hospitalization for stroke compared to usual care.

METHOD

The primary outcome measures were changes in functional capacity, strength, muscle mass, and muscle degradation. The secondary outcomes were changes in serum biomarkers related to inflammation, fibrosis, anabolism, and muscle synthesis. In addition, a follow-up 90 days after the stroke verified functional capacity, strength, quality of life, and mortality. Following admission for an acute stroke, participants received either creatine (10 g) or a visually identical placebo (10 g) orally twice daily. Both groups received supplementation with protein to achieve the goal of 1.5 g of protein/kg of body weight/day and underwent daily mobility training during seven days of hospitalization.

RESULTS

Thirty older people were included in two similar groups concerning baseline attributes (15-treatment/15-placebo).

CONCLUSIONS

Creatine supplementation did not influence functional capacity, strength, or muscle mass during the first 7 days or outcomes 90 days after stroke. There were no serious adverse events associated with creatine supplementation. However, it decreased progranulin levels, raising a new possibility of creatine action. This finding needs further exploration to understand the biological significance of creatine-progranulin interaction.

MeSH

Muscles, Hospitalization, Stroke, Food, Progranulins, Creatine, Sarcopenia